Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its 2024 Investor Day. While these events are often catalysts for stock, ...

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase ...

The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot. Merck's Vaxneuvance ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.